Assessing Value: Promise & Pitfalls

Washington, DC

The Liaison Capitol Hill
415 New Jersey Ave., NW
Metropolitan Ballroom (Lobby Level)
Washington, DC 20001
9:00 AM - 4:00 PM ET
 

 

Value assessment frameworks are a new and evolving field, and have the potential to have a tremendous impact on patient treatment decisions, as well as on coverage and reimbursement decisions. These frameworks emerged in the U.S. in response to multiple factors, including an increased focus on patient-centered care, alternative payment models intended to incentivize health care value, and public attention on new high-priced therapies.

>> Watch the event archive via Livestream.

Overview

While the current value assessment frameworks have much to teach us, initial comparisons of these frameworks highlight the important differences and analytic challenges that still remain. Continued improvements are necessary to address the different perspectives inherent in assessing value.

During the conference, we shared research that evaluated how existing frameworks align with NPC’s Guiding Practices for Patient-Centered Value Assessment and explored the variable outputs from multiple myeloma treatment assessments conducted using four different frameworks. A broad range of stakeholders shared their perspectives on the research, uncovering the lessons learned to date, and how best to advance the field of value assessment.

Follow the event on Twitter using #npcvalueconf and NPC at @npcnow.

Agenda

AGENDA

8:30 am
Continental Breakfast and Registration Open

9:00 am
Welcome & Opening Comments

  • Dan Leonard, MA, President, National Pharmaceutical Council (NPC)

9:15 am
Framing the Discussion: Why Assessing Value Is Important and Why It’s Important to Do It Right

9:45 am
Moving Value Frameworks from Fledgling to Functional - Presentation of Research

  • Cliff Goodman, PhD, Senior Vice President and Director, Center for Comparative Effectiveness Research, Lewin Group

10:15 am
Break

10:30 am
Moving Value Frameworks from Fledgling to Functional - Panel Discussion

  • Michael Sherman, MD, MBA, MS, Senior Vice President and Chief Medical Officer, Harvard Pilgrim Health Care 
  • Eleanor M. Perfetto, PhD, MD, Senior Vice President, Strategic Initiatives, National Health Council 
  • Josh Ofman, MD, MSHS, Senior Vice President, Global Value, Access & Policy, Amgen
  • Peter J. Neumann, ScD, Director, Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center; Professor of Medicine, Tufts University School of Medicine

11:45 am
Lunch

12:30 pm
Why Four Frameworks (Should) Arrive at Different Conclusions: A Case Study of Multiple Myeloma Reviews - Presentation of Research

  • Cliff Goodman, PhD, Senior Vice President and Director, Center for Comparative Effectiveness Research, Lewin Group

1:00 pm
Break

1:10 pm
Why Four Frameworks (Should) Arrive at Different Conclusions: A Case Study of Multiple Myeloma Reviews - Framework Developers

  • Steven (Steve) D. Pearson, MD, MSc, Founder and President, Institute for Clinical and Economic Review
  • Peter B. Bach, MD, Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center
  • Lowell E. Schnipper, MD, Theodore and Evelyn Berenson Professor of Medicine, Harvard Medical School and Clinical Director, Cancer Center, Chief, Hematology-Oncology Division, Beth Israel Deaconess Medical Center
  • Robert (Bob) W. Carlson, MD, Chief Executive Officer, National Comprehensive Cancer Network

2:20 pm
Break

2:30 pm
Why Four Frameworks (Should) Arrive at Different Conclusions: A Case Study of Multiple Myeloma Reviews - Other Points of View

  • Ethan Basch, MD, MSc, Director, Cancer Outcomes Research Program; Professor, Medicine and Public Health, UNC-Chapel Hill, Cancer Prevention and Control 
  • Roy Beveridge, MD, Chief Medical Officer, Humana
  • Gwen Darien, Executive Vice President for Patient Advocacy, National Patient Advocate Foundation
  • Stephen J. Noga, MD, PhD, Senior Medical Director for Global Medical Affairs, Takeda Oncology

3:40 pm
Closing Remarks

  • Robert (Bobby) W. Dubois, MD, PhD, Executive Vice President & Chief Science Officer, NPC
  • Cliff Goodman, PhD, Senior Vice President and Director, Center for Comparative Effectiveness Research, Lewin Group

4:00 pm 
Adjourn

Contact

Questions? Contact:
Tanya Bailey
Membership & Meetings Associate
202-827-2092
tbailey@npcnow.org

 

Sessions

Caregiver Action Network
 
 
 
Global Liver Institute
 
 
 
 
 

 
 
 
National Psoriasis Foundation